<span item_type="fundamental" item_id="1eb22ee241ac90e1c4c1380e37ed6a9c" counter_id="ST/US/SINT" env="prod"></span><span item_type="announcement" item_id="582313542658949633" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 208 K, beating the estimate of USD 200 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -3.46.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -3.385 M.</p><p></p><h3>Financial Metrics by Segment</h3><h4>Segment Revenue</h4><ul><li><strong>Total Revenue</strong>: $0.2 million, a decrease from $0.8 million in Q3 2024, primarily due to a reduction in grant revenue.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1269026/000149315225022125/ex99-1.htm"></span></li></ul><h4>Operational Metrics</h4><ul><li><strong>Operating Expenses</strong>: Approximately $3.4 million, a decrease of 51% year-over-year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1269026/000149315225022125/ex99-1.htm"></span></li><li><strong>Operating Loss</strong>: $3.4 million compared to $6.4 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1269026/000149315225022125/ex99-1.htm"></span></li><li><strong>Net Loss</strong>: $3.5 million, representing a loss of $1.19 per fully diluted share, compared to a net loss of $6.2 million representing a loss of $6.96 per fully diluted share in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1269026/000149315225022125/ex99-1.htm"></span></li><li><strong>Adjusted EBITDA Loss</strong>: $2.3 million in Q3 2025 compared to $6.1 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1269026/000149315225022125/ex99-1.htm"></span></li></ul><h4>Cash Flow</h4><ul><li><strong>Cash and Cash Equivalents</strong>: $6.25 million on September 30, 2025, compared with $3.60 million on December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1269026/000149315225022125/ex99-1.htm"></span></li></ul><h4>Unique Metrics</h4><ul><li><strong>Initial Product Revenue</strong>: Recorded first commercial revenue from the private-labeled orthobiologic product OsseoSculpt™.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1269026/000149315225022125/ex99-1.htm"></span></li><li><strong>Facility Optimization</strong>: Executed a sublease of the Armor facility, estimated to save up to approximately $950,000 in lease costs over the sublease term.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1269026/000149315225022125/ex99-1.htm"></span></li><li><strong>Strengthened Liquidity</strong>: Raised an additional $4.3 million in gross proceeds through warrant inducement and common stock warrant exercises.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1269026/000149315225022125/ex99-1.htm"></span></li></ul><h4>Outlook / Guidance</h4><ul><li>SINTX’s near-term priorities include preparing the SINAPTIC wedge system for launch, expanding clinical and key opinion leader engagement in targeted surgical specialties, and leveraging its material science into adjacent indications.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1269026/000149315225022125/ex99-1.htm"></span></li><li>Management intends to continue evaluating partnering, licensing, and capital formation options to accelerate market access and enhance shareholder value.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1269026/000149315225022125/ex99-1.htm"></span></li></ul>

SiNtx Tech | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 208 K